CN114681459B - 伊布替尼药物组合物、其制备方法及应用 - Google Patents
伊布替尼药物组合物、其制备方法及应用 Download PDFInfo
- Publication number
- CN114681459B CN114681459B CN202111557994.3A CN202111557994A CN114681459B CN 114681459 B CN114681459 B CN 114681459B CN 202111557994 A CN202111557994 A CN 202111557994A CN 114681459 B CN114681459 B CN 114681459B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- ibutinib
- ibutenib
- tween
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 18
- 239000007957 coemulsifier Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 21
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical group CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 claims description 18
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 18
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 18
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 18
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 18
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 18
- 239000004530 micro-emulsion Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 10
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims description 4
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 5
- 238000003860 storage Methods 0.000 abstract description 5
- 238000010579 first pass effect Methods 0.000 abstract description 3
- 230000002440 hepatic effect Effects 0.000 abstract description 3
- 230000002349 favourable effect Effects 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 241000219000 Populus Species 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
Description
成分 | 重量(mg/粒) | 占比(重量%) |
伊布替尼 | 100 | 9.09 |
丙二醇单辛酸酯 | 229.5 | 20.86 |
吐温20 | 536.4 | 48.75 |
二乙二醇单乙基醚 | 234.3 | 21.30 |
成分 | 重量(mg/粒) | 占比(重量%) |
伊布替尼 | 100 | 9.09 |
丙二醇单辛酸酯 | 370.7 | 33.70 |
吐温20 | 438.0 | 39.82 |
二乙二醇单乙基醚 | 191.3 | 17.39 |
成分 | 重量(mg/粒) | 占比(重量%) |
伊布替尼 | 100 | 9.17 |
丙二醇单辛酸酯 | 297.1 | 27.25 |
吐温20 | 462.2 | 42.39 |
二乙二醇单乙基醚 | 231.1 | 21.19 |
成分 | 重量(mg/粒) | 占比(重量%) |
伊布替尼 | 100 | 9.07 |
丙二醇单辛酸酯 | 200.1 | 18.16 |
吐温20 | 601.5 | 54.58 |
二乙二醇单乙基醚 | 200.5 | 18.19 |
项目 | 实施例1 | 实施例2 | 实施例3 | 实施例4 |
粒径(nm) | 237.02 | 285.73 | 400.68 | 81.61 |
Claims (8)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011603222 | 2020-12-29 | ||
CN2020116032224 | 2020-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114681459A CN114681459A (zh) | 2022-07-01 |
CN114681459B true CN114681459B (zh) | 2024-02-27 |
Family
ID=82136014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111557994.3A Active CN114681459B (zh) | 2020-12-29 | 2021-12-20 | 伊布替尼药物组合物、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114681459B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115192522A (zh) * | 2022-08-24 | 2022-10-18 | 烟台慧暄医药科技有限公司 | 一种含有伊布替尼的组合物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104039325A (zh) * | 2011-10-19 | 2014-09-10 | 药品循环公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的用途 |
CN113440481A (zh) * | 2021-08-13 | 2021-09-28 | 湖南慧泽生物医药科技有限公司 | 伊布替尼的自微乳组合物 |
-
2021
- 2021-12-20 CN CN202111557994.3A patent/CN114681459B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104039325A (zh) * | 2011-10-19 | 2014-09-10 | 药品循环公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的用途 |
CN113440481A (zh) * | 2021-08-13 | 2021-09-28 | 湖南慧泽生物医药科技有限公司 | 伊布替尼的自微乳组合物 |
Non-Patent Citations (2)
Title |
---|
冯年平等主编.《中药经皮给药与功效性化妆品》.中国医药科技出版社,2019,参见第172-174页. * |
吴清主编.《物理药剂学》.中国中医药出版社,2018,参见第334页. * |
Also Published As
Publication number | Publication date |
---|---|
CN114681459A (zh) | 2022-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI533866B (zh) | 卡巴利他索(cabazitaxel)之新穎抗腫瘤用途 | |
EP4035657A1 (en) | Drug composition containing abiraterone acetate, and preparation method therefor and application thereof | |
CN1198616C (zh) | 抗肿瘤化合物的口服制剂 | |
CN114681459B (zh) | 伊布替尼药物组合物、其制备方法及应用 | |
Liu et al. | Preparation, characterization, and evaluation of antitumor effect of Brucea javanica oil cationic nanoemulsions | |
CN101102747B (zh) | 基于植物甾醇和甘油酯的反胶束及其治疗用途 | |
CN109069503A (zh) | 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用 | |
CN100341577C (zh) | 经皮吸收制剂 | |
US8293787B2 (en) | Gallium compositions for the treatment of liver cancer and methods of use | |
CN111012745A (zh) | 一种阿比特龙口服乳剂及其制备方法 | |
CN1283235C (zh) | 清澈稳定的丙泊酚组合物 | |
US20140275137A1 (en) | Tetrandrine family pharmaceutical formulations and method | |
CN1857208A (zh) | 同载抗代谢药物及其增效剂的抗癌缓释注射剂 | |
CN113750032A (zh) | 一种口服的阿比特龙药物组合物及其制备方法及用途 | |
US20140073670A1 (en) | Pharmaceutical composition comprising fexofenadine | |
CN107137349B (zh) | 一种藤黄酸纳米混悬剂及其制备方法 | |
JP2009541229A (ja) | 特に局所投与を目的とした注射用医薬組成物 | |
CZ2004945A3 (cs) | Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo | |
CN1919339A (zh) | 含有蛋白的葫芦素纳米制剂及制备方法和用途 | |
CN111297876B (zh) | 一种塞来昔布胶束和和厚朴酚胶束药物联用控释***及其制备方法 | |
CN107281163B (zh) | 羧基化合物在促进载药纳米粒微球口服吸收方面的应用 | |
CN115721659A (zh) | 一种表柔比星复方制剂及其制备方法和应用 | |
CN1511037A (zh) | 非肠道使用的雌莫司汀磷酸盐和白蛋白的制剂 | |
CN114569545B (zh) | 一种稳定的米托蒽醌制剂 | |
US11504339B2 (en) | Compositions comprising urolithin a and uses thereof in treating kidney injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Applicant after: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Applicant after: Shanghai bozhiyan new drug research Co.,Ltd. Address before: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Applicant before: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. Applicant before: Shanghai bozhiyan new drug research Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230516 Address after: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Applicant after: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Address before: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Applicant before: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Applicant before: Shanghai bozhiyan new drug research Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |